Apogee Therapeutics (APGE) Competitors $36.35 +0.34 (+0.93%) As of 02:48 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock APGE vs. RYTM, RNA, NUVL, ABVX, AXSM, CRSP, MRUS, VKTX, TGTX, and ACADShould you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Rhythm Pharmaceuticals (RYTM), Avidity Biosciences (RNA), Nuvalent (NUVL), Abivax (ABVX), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Merus (MRUS), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. Apogee Therapeutics vs. Its Competitors Rhythm Pharmaceuticals Avidity Biosciences Nuvalent Abivax Axsome Therapeutics CRISPR Therapeutics Merus Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals Apogee Therapeutics (NASDAQ:APGE) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings and media sentiment. Is APGE or RYTM more profitable? Apogee Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -117.13%. Apogee Therapeutics' return on equity of -34.65% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Apogee TherapeuticsN/A -34.65% -32.76% Rhythm Pharmaceuticals -117.13%-1,831.43%-48.33% Which has more volatility & risk, APGE or RYTM? Apogee Therapeutics has a beta of 1.43, suggesting that its share price is 43% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 2.38, suggesting that its share price is 138% more volatile than the S&P 500. Do insiders and institutionals believe in APGE or RYTM? 79.0% of Apogee Therapeutics shares are owned by institutional investors. 42.8% of Apogee Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Rhythm Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has stronger valuation & earnings, APGE or RYTM? Apogee Therapeutics has higher earnings, but lower revenue than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApogee TherapeuticsN/AN/A-$182.15M-$4.13-8.80Rhythm Pharmaceuticals$130.13M51.52-$260.60M-$3.01-33.53 Does the media refer more to APGE or RYTM? In the previous week, Rhythm Pharmaceuticals had 12 more articles in the media than Apogee Therapeutics. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 5 mentions for Apogee Therapeutics. Rhythm Pharmaceuticals' average media sentiment score of 0.80 beat Apogee Therapeutics' score of -0.16 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Rhythm Pharmaceuticals 10 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate APGE or RYTM? Apogee Therapeutics currently has a consensus price target of $99.00, indicating a potential upside of 172.31%. Rhythm Pharmaceuticals has a consensus price target of $101.57, indicating a potential upside of 0.64%. Given Apogee Therapeutics' higher possible upside, analysts clearly believe Apogee Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 1 Strong Buy rating(s) 3.07 SummaryApogee Therapeutics and Rhythm Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get Apogee Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APGE vs. The Competition Export to ExcelMetricApogee TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.67B$3.12B$5.76B$9.55BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-8.7820.4630.4325.11Price / SalesN/A237.31392.2187.48Price / CashN/A42.3737.0358.50Price / Book2.717.959.016.20Net Income-$182.15M-$54.72M$3.26B$265.38M7 Day Performance-4.63%1.56%1.00%-1.25%1 Month Performance-7.04%5.71%4.19%-0.81%1 Year Performance-24.81%9.01%28.39%18.83% Apogee Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APGEApogee Therapeutics3.44 of 5 stars$36.36+0.9%$99.00+172.3%-26.5%$1.67BN/A-8.7891RYTMRhythm Pharmaceuticals3.7232 of 5 stars$94.31+2.5%$101.57+7.7%+116.4%$6.11B$130.13M-31.33140News CoverageRNAAvidity Biosciences3.1499 of 5 stars$45.75-1.2%$67.00+46.4%-1.2%$5.96B$10.90M-15.25190News CoverageOptions VolumeNUVLNuvalent3.1902 of 5 stars$74.95+1.1%$119.60+59.6%-4.0%$5.32BN/A-15.3040News CoverageAnalyst ForecastInsider TradeABVXAbivax3.3596 of 5 stars$69.00-1.6%$92.33+33.8%+531.7%$5.30BN/A0.0061Short Interest ↑AXSMAxsome Therapeutics4.7817 of 5 stars$103.96-0.8%$178.00+71.2%+32.7%$5.23B$385.69M-20.50380Positive NewsCRSPCRISPR Therapeutics3.7612 of 5 stars$55.41+0.7%$71.60+29.2%+8.2%$5.00B$37.31M-10.20460MRUSMerus2.2082 of 5 stars$64.60+0.9%$88.50+37.0%+20.0%$4.84B$36.13M-11.7537News CoverageVKTXViking Therapeutics3.9747 of 5 stars$38.20+0.8%$86.92+127.6%-61.2%$4.26BN/A-24.9620Trending NewsAnalyst ForecastOptions VolumeTGTXTG Therapeutics4.3113 of 5 stars$26.39-1.2%$46.25+75.3%+14.6%$4.24B$329M71.32290Positive NewsACADACADIA Pharmaceuticals3.9104 of 5 stars$24.82+0.9%$28.88+16.3%+60.2%$4.15B$957.80M18.66510Insider Trade Related Companies and Tools Related Companies RYTM Competitors RNA Competitors NUVL Competitors ABVX Competitors AXSM Competitors CRSP Competitors MRUS Competitors VKTX Competitors TGTX Competitors ACAD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APGE) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apogee Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apogee Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access